神经节苷脂联合依达拉奉治疗老年急性脑梗死患者的效果及不良反应率评价

Evaluated the Efficacy and Adverse Reaction Rate of Ganglioside Combined with Edaravone in the Treatment of Elderly Patients with Acute Cerebral Infarction

目的:急性脑梗死老年患者应用神经节苷脂与依达拉奉联合治疗的效果、不良反应情况观察。方法:选取2017年10月~2018年10月本院诊治的110例急性脑梗死老年患者,随机分为两组,对照组给予依达拉奉单独治疗,研究组给予神经节苷脂与依达拉奉联合方案进行治疗,分析两组的炎症因子、神经功能与不良反应情况。结果:治疗前两组的IL-6、TNF-α及CRP无明显差异(P> 0.05)。治疗后两组均降低,研究组的IL-6[(19.48±5.52)pg/ml]、TNF-α[(17.49±4.28)nmol/L]及CRP[(13.57±3.28)mg/L]等炎症因子均比对照组低,差异具统计学意义(P <0.05);且研究组的美国国立卫生院神经功能缺损评分(NIHSS评分)为(7.23±2.46)分,比对照组的(13.58±3.92)分低,差异具统计学意义(P <0.05)。结论:急性脑梗死老年患者应用神经节苷脂与依达拉奉联合治疗能改善患者的神经功能及炎症因子,且具用药安全性。

Objective: Study the efficacy and adverse reactions of ganglioside and edaravone in elderly patients with acute cerebral infarction. Methods: A total of 110 elderly patients with acute cerebral infarction were enrolled in our hospital from October 2017 to May 2018. They were randomly divided into two groups. The control group was given edaravone treatment. The study group was given the combination of ganglioside and edaravone, then analyzed the inflammatory factors,neurological function and adverse reactions of two groups. Results: There was no significant difference in IL-6, TNF-α and CRP between the two groups before treatment(P>0.05). After treatment, both groups were reduced, and the IL-6(19.48±5.52)pg/ml, the inflammatory factors such as TNF-α(17.49±4.28)nmol/L and CRP(13.57±3.28)mg/L in study group were lower than the control group, the difference was statistically significant(P<0.05);and the National Institute of Health stroke scale(NIHSS) score of the study group was(7.23±2.46), which was lower than the control group(13.58±3.92), and the difference was statistically significant(P <0.05). Conclusion: The combination of ganglioside and edaravone in elderly patients with acute cerebral infarction could improve neurological function and inflammatory factors in patients with cerebral infarction.